John Marshall

MD, FRCSC, FACS, FCAHS

Scientist

Biography

Dr. John Marshall is a Professor of Surgery at the University of Toronto, and an Intensivist at St. Michael’s Hospital in Toronto, Canada.  His academic interests are sepsis, trauma, and the innate immune response.  His laboratory studies the cellular mechanisms that prolong neutrophil survival in critical illness by preventing neutrophil programmed cell death, or apoptosis.  Professor Marshall has an active clinical research interest in sepsis and Intensive Care Unit-acquired infection, and in the design of clinical trials and outcome measures.  He has published 440 manuscripts, and 85 book chapters, and is the editor of 2 books.  He is the founding chair of the International Forum of Acute Care Trialists (InFACT) – a global network of investigator-led critical care clinical research groups, and past Secretary-General of the World Federation of Societies of Intensive and Critical Care Medicine.  He co-chairs the WHO R&D Working Group on the Clinical Characterization and Management of COVID-19.  He is past-chair of the International Sepsis Forum, past-President of the Surgical Infection Society, and past-chair of the Canadian Critical Care Trials Group.  He has given invited lectures at more than 540 meetings around the world, and is an Associate Editor of the journals Critical Care Medicine and Critical care.”

Recent Publications

  1. BALANCE Investigators, for the Canadian Critical Care Trials Group, the Association of Medical Microbiology and Infectious Disease Canada Clinical Research Network, the Australian and New Zealand Intensive Care Society Clinical Trials Group, and the Australasian Society for Infectious Diseases Clinical Research Network, Daneman, N, Rishu, A, Pinto, R, Rogers, BA, Shehabi, Y et al.. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections. N Engl J Med. 2024; :. doi: 10.1056/NEJMoa2404991. PubMed PMID:39565030 .
  2. Chen, ZZ, Dufresne, J, Bowden, P, Celej, D, Miao, M, Marshall, JG et al.. Micro scale chromatography of human plasma proteins for nano LC-ESI-MS/MS. Anal Biochem. 2024;697 :115694. doi: 10.1016/j.ab.2024.115694. PubMed PMID:39442602 .
  3. Baillie, JK, Angus, D, Burnham, K, Calandra, T, Calfee, C, Gutteridge, A et al.. Causal inference can lead us to modifiable mechanisms and informative archetypes in sepsis. Intensive Care Med. 2024; :. doi: 10.1007/s00134-024-07665-4. PubMed PMID:39432104 PubMed Central PMC7616750.
  4. Chen, ZZ, Dufresne, J, Bowden, P, Miao, M, Marshall, JG. Trypsin Digestion Conditions of Human Plasma for Observation of Peptides and Proteins from Tandem Mass Spectrometry. ACS Omega. 2024;9 (40):41343-41354. doi: 10.1021/acsomega.4c03955. PubMed PMID:39398168 PubMed Central PMC11465567.
  5. Lee, SH, Bushra, M, Qiu, L, Griffiths, AM, Turpin, W, Croitoru, K et al.. Early Life Exposure to Parental Crohn's Disease Is Associated With Offspring's Gut Microbiome, Gut Permeability, and Increased Risk of Future Crohn's Disease. Gastroenterology. 2024; :. doi: 10.1053/j.gastro.2024.09.033. PubMed PMID:39384162 .
  6. Fischer, A, Mac, S, Freiman, ES, Marshall, JK, Rand, K, Ramos-Goñi, JM et al.. Cost Effectiveness of Sequencing Vedolizumab as First-Line Biologic in Ulcerative Colitis and Crohn's Disease in Canada: An Analysis Using Real-World Evidence from the EVOLVE Study. Pharmacoecon Open. 2024; :. doi: 10.1007/s41669-024-00523-5. PubMed PMID:39377864 .
  7. Lother, SA, Tennenhouse, L, Rabbani, R, Abou-Setta, AM, Askin, N, Turgeon, AF et al.. The association of antiplatelet agents with mortality among patients with non-COVID-19 community-acquired pneumonia: a systematic review and meta-analysis. Res Pract Thromb Haemost. 2024;8 (5):102526. doi: 10.1016/j.rpth.2024.102526. PubMed PMID:39262648 PubMed Central PMC11387270.
  8. Vale, C, Godolphin, PJ, Fisher, D, Horby, PW, Kosiborod, MN, Hochman, JS et al.. Sodium-glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2024;12 (10):735-747. doi: 10.1016/S2213-8587(24)00219-5. PubMed PMID:39250923 .
  9. Olivera, PA, Martinez-Lozano, H, Leibovitzh, H, Xue, M, Neustaeter, A, Espin-Garcia, O et al.. Healthy First-Degree Relatives From Multiplex Families vs Simplex Families Have a Higher Subclinical Intestinal Inflammation, a Distinct Fecal Microbial Signature, and Harbor a Higher Risk of Developing Crohn's Disease. Gastroenterology. 2024; :. doi: 10.1053/j.gastro.2024.08.031. PubMed PMID:39236898 .
  10. Seow, CH, Marshall, JK, Stewart, E, Pettengell, C, Ward, R, Afif, W et al.. The relationship among vedolizumab drug concentrations, biomarkers of inflammation, and clinical outcomes in a Canadian real-world study. J Can Assoc Gastroenterol. 2024;7 (4):290-298. doi: 10.1093/jcag/gwae010. PubMed PMID:39139218 PubMed Central PMC11317629.
Search PubMed

Affiliations & Other Activities

  • Scientist, Keenan Research Centre for Biomedical Science
  • Trauma Surgeon and Intensivist, St. Michael’s Hospital
  • Professor, Department of Surgery, University of Toronto